Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescript...
A Study to Evaluate the Quality of Life in Male and Female Adult Participants With Severe Asthma Treated With Dupilumab in a Real-world Setting
- Conditions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 112
- Registration Number
- NCT06018441
- Locations
- 🇫🇷
Investigational Site, France, France
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
- Conditions
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 166
- Registration Number
- NCT06015308
- Locations
- 🇺🇸
Clinical Research Center of Alabama - Homewood- Site Number : 8401101, Birmingham, Alabama, United States
🇺🇸Center for Dermatology and Plastic Surgery- Site Number : 8401119, Scottsdale, Arizona, United States
🇺🇸Orange County Clinical Trials- Site Number : 8401271, Anaheim, California, United States
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 300
- Registration Number
- NCT05991323
- Locations
- 🇺🇸
Medical Dermatology Specialists Site Number : 8400005, Phoenix, Arizona, United States
🇺🇸Medical Dermatology Specialists- Site Number : 8400005, Phoenix, Arizona, United States
🇺🇸Saguaro Dermatology Associates, LLC - Probity - PPDS- Site Number : 8400024, Phoenix, Arizona, United States
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 48
- Registration Number
- NCT05983068
- Locations
- 🇺🇸
National Jewish Center Site Number : 8400001, Denver, Colorado, United States
🇺🇸St. Louis University SLUCare Academic Pavilion Site Number : 8400006, Saint Louis, Missouri, United States
🇺🇸New York University Langone Health Site Number : 8400004, New York, New York, United States
Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 182
- Registration Number
- NCT05976386
- Locations
- 🇺🇸
Clinical Pharmacology of Miami-Site Number:8400001, Miami, Florida, United States
A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 38
- Registration Number
- NCT05976360
- Locations
- 🇺🇸
Prism Research-Site Number:840002, Saint Paul, Minnesota, United States
🇺🇸Biokinetic Clinical Applications-Site Number:840003, Springfield, Missouri, United States
A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 38
- Registration Number
- NCT05976373
- Locations
- 🇺🇸
Prism Research-Site Number:840001, Saint Paul, Minnesota, United States
A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 32
- Registration Number
- NCT05972629
- Locations
- 🇧🇷
Hospital de Clinicas de Porto Alegre- Site Number : 0760001, Porto Alegre, Rio Grande Do Sul, Brazil
🇺🇸Children's Hospital IMD Clinic- Site Number : 8400015, Aurora, Colorado, United States
🇺🇸University of Florida-Genetics Site Number : 8400010, Gainesville, Florida, United States
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 200
- Registration Number
- NCT05911763
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center Site Number : 8400008, Gilbert, Arizona, United States
🇺🇸Loma Linda University Site Number : 8400015, Loma Linda, California, United States
🇺🇸Orthopedic Institute for Children Site Number : 8400004, Los Angeles, California, United States
Implementation and Evaluation of a Rare Disease Algorithm to Identify Persons at Risk of Gaucher Disease Using Data From Electronic Health Records (EHRs) in the United States (Project Searchlight)
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 13
- Registration Number
- NCT05908656
- Locations
- 🇺🇸
University of Florida 655 W 8th St- Site Number : 8400003, Gainesville, Florida, United States
🇺🇸Metropolitan Hospital Center- Site Number : 8400001, New York, New York, United States
🇺🇸Aurora Research Institute LLC- Site Number : 8400002, Milwaukee, Wisconsin, United States